Galectin Therapeutics Inc (GALT) stock
GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.91−0.11 (-3.64%)
Close on Nov 17, 2026Market cap $293.47MP/E –Yield –
Galectin Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Galectin Therapeutics's ebitda for the twelve months ending Dec 31, 2017 was -$16.25M. For fiscal 2024 it was -$42.43M. The highest annual figure on record is -$4.87M in fiscal 2010.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$42.43M | – |
| FY2023 | Dec 31, 2023 | -$38.07M | – |
| FY2022 | Dec 31, 2022 | -$38.35M | – |
| FY2021 | Dec 31, 2021 | -$30.18M | – |
| FY2020 | Dec 31, 2020 | -$23.44M | – |
| FY2019 | Dec 31, 2019 | -$13.44M | – |
| FY2018 | Dec 31, 2018 | -$13.60M | – |
| FY2017 | Dec 31, 2017 | -$16.25M | – |
| FY2016 | Dec 31, 2016 | -$21.47M | – |
| FY2015 | Dec 31, 2015 | -$20.07M | – |
| FY2014 | Dec 31, 2014 | -$15.42M | – |
| FY2013 | Dec 31, 2013 | -$12.09M | – |
| FY2012 | Dec 31, 2012 | -$9.89M | – |
| FY2011 | Dec 31, 2011 | -$10.40M | – |
| FY2010 | Dec 31, 2010 | -$4.87M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2017 | Dec 31, 2017 | -$2.37M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.41M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.51M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.95M | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.60M | – |
| Q3 FY2016 | Sep 30, 2016 | -$4.54M | – |
See a number that looks wrong?